Cyclerion Therapeutics, Inc. Common Stock earnings per share and revenue
On 12. Nov. 2025, CYCN reported earnings of -0.30 USD per share (EPS) for Q3 25, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached 880.00 tausend, compared to an expected --, with a --% difference. The market reacted with a +1.41% price change (close before vs. close after earnings).
Looking ahead to Q4 25, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were Cyclerion Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Cyclerion Therapeutics, Inc. Common Stock reported EPS of -$0.30, missing estimates by --, and revenue of $880.00K, -- -- expectations.
How did the market react to Cyclerion Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 1.41%, changed from $1.42 before the earnings release to $1.44 the day after.
When is Cyclerion Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 02. März 2026.
What are the forecasts for Cyclerion Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Cyclerion Therapeutics, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q4 2025.